The estimated Net Worth of Daniel J Levangie is at least $2.57 Milhão dollars as of 1 March 2024. Mr. Levangie owns over 5,000 units of Exact Sciences stock worth over $1,473,157 and over the last 17 years he sold EXAS stock worth over $764,905. In addition, he makes $329,023 as Independent Director at Exact Sciences.
Daniel has made over 8 trades of the Exact Sciences stock since 2007, according to the Form 4 filled with the SEC. Most recently he sold 5,000 units of EXAS stock worth $287,500 on 1 March 2024.
The largest trade he's ever made was exercising 267,959 units of Exact Sciences stock on 24 October 2007 worth over $8,062,886. On average, Daniel trades about 10,019 units every 153 days since 2007. As of 1 March 2024 he still owns at least 22,975 units of Exact Sciences stock.
You can see the complete history of Mr. Levangie stock trades at the bottom of the page.
Daniel J. Levangie serves as Independent Director of the Company. He has served as a director since July 2010. He is an experienced executive and corporate director with senior operating experience in the field of medical devices and in vitro diagnostics. Mr. Levangie is co-founder and manager of ATON Partners, a private investment firm, and Chairman, President & CEO of CereVasc, LLC, an early-stage medical device company. From 2013 through January 2017, Mr. Levangie served as President of Insulet Drug Delivery Systems. From 2011 through 2013, Mr. Levangie was chief executive officer of Dune Medical Devices, Inc. and co-founder and managing partner of Constitution Medical Investors, Inc., a Boston-based private investment and product development firm acquired by Roche Diagnostics Corporation in July 2013. Prior to the above, Mr. Levangie held a variety of executive management positions with Cytyc Corporation until the acquisition of Cytyc by Hologic, Inc. in October 2007. These positions include executive vice president and chief operating officer, chief executive officer and president of Cytyc Health Corporation, executive vice president and chief commercial officer and president, Cytyc Surgical Products Division. Prior to joining Cytyc Corporation in 1992, Mr. Levangie held a number of sales, marketing and management positions with Abbott Laboratories, a diversified healthcare company. Mr. Levangie is currently a director of CereVasc, LLC, Dune Medical Devices and Renovia, Inc. He previously served as a director of Insulet Corporation, a medical device company (Nasdaq: PODD), Liposcience, Inc., a diagnostics company (formerly Nasdaq: LIPO), ev3, Inc., a medical device company, and Hologic, Inc., a diagnostic, imaging systems and surgical products company (Nasdaq: HOLX). Mr. Levangie is a member of the Advisory Board of the Barnett Institute of Northeastern University and is a trustee of Excel Charter School, East Boston. Mr. Levangie earned a bachelor's degree in pharmacy from Northeastern University.
As the Independent Director of Exact Sciences, the total compensation of Daniel Levangie at Exact Sciences is $329,023. There are 20 executives at Exact Sciences getting paid more, with Kevin Conroy having the highest compensation of $18,716,500.
Daniel Levangie is 69, he's been the Independent Director of Exact Sciences since 2010. There are 3 older and 22 younger executives at Exact Sciences. The oldest executive at Exact Sciences Corp. is James Doyle, 74, who is the Independent Director.
Daniel's mailing address filed with the SEC is C/O EXACT SCIENCES CORP., 5505 ENDEAVOR LANE, MADISON, WI, 53719.
Over the last 21 years, insiders at Exact Sciences have traded over $118,141,352 worth of Exact Sciences stock and bought 191,930 units worth $1,451,887 . The most active insiders traders include Kevin T Conroy, Edwin M Jr Kania, eManeesh Arora. On average, Exact Sciences executives and independent directors trade stock every 12 days with the average trade being worth of $1,667,056. The most recent stock trade was executed by Brian Baranick on 5 August 2024, trading 2,712 units of EXAS stock currently worth $173,893.
exact sciences is a molecular diagnostics company focused on colorectal cancer. the company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. stool-based dna (sdna) technology is included in the colorectal cancer screening guidelines of the american cancer society and the u.s. multi-society task force on colorectal cancer. for more information on exact sciences' noninvasive colon cancer screening test, visit cologuardtest.com
Exact Sciences executives and other stock owners filed with the SEC include: